| topic | best-supported conclusion | evidence type/key quantitative detail | confidence/caveat |
|---|---|---|---|
| Identity and domains | The target is human LOXL2 (lysyl oxidase-like 2), a LOX-family secreted amine oxidase with four N-terminal SRCR domains and a conserved C-terminal catalytic domain. | Concordant biochemical/structural reviews and recombinant protein studies; UniProt-compatible architecture repeatedly reported. Full-length protein is ~100 kDa. (pqac-00000002, pqac-00000004) | High; identity and domain architecture are well established. |
| Catalytic chemistry and cofactors | LOXL2 catalyzes oxidative deamination of peptidyl lysine/hydroxylysine to reactive aldehydes that drive covalent ECM cross-linking; activity is copper- and LTQ-dependent. | LTQ derives from Lys653 and Tyr689; catalytic domain contains the His-X-His-X-His copper-binding motif. Model-substrate kinetics reported for 1,5-diaminopentane/spermine: Km ~1 mM, kcat ~0.02 s^-1. (pqac-00000004, pqac-00000002) | High for amine-oxidase chemistry/cofactor assignment; kinetic constants are mainly from model substrates rather than native fibrillar substrates. |
| Processing and localization | LOXL2 is synthesized as a precursor, secreted, and can be proteolytically processed by PACE4 to remove SRCR1-2 without abolishing in vitro amine-oxidase activity. The major functional site is extracellular matrix. | Cleavage site reported as Arg314-Phe315-Arg316-Lys317↓Ala318; processed form ~60 kDa. Full-length LOXL2 is mostly monomer, with some concentration-dependent dimerization/higher oligomers; at ≥0.88 mg/mL: 83.6% monomer, 11.6% dimer, 4.7% tetramer+pentamer. (pqac-00000002, pqac-00000003, pqac-00000017) | High for secretion/processing; physiological significance of SRCR cleavage remains incompletely resolved. Proposed intracellular roles exist but are less securely established than ECM-localized catalysis. |
| Physiological substrates | Best-supported physiological substrates are extracellular matrix proteins, especially collagen and elastin precursors; direct evidence is strongest for tropoelastin and collagen IV. | Proteomics demonstrated LOXL2-mediated tropoelastin deamination/cross-linking and formation of elastin-like material with mature-elastin-like mechanical properties; LOXL2 also oxidizes collagen IV and can oxidize lysines in PDGFRβ extracellular domain. (pqac-00000005, pqac-00000002, pqac-00000003) | High for ECM substrate class; substrate-site specificity across all collagen isoforms is still incomplete. PDGFRβ oxidation broadens substrate scope beyond structural ECM proteins. |
| Pathways and disease mechanisms | LOXL2 primarily functions in ECM remodeling, matrix stiffening, and collagen/elastin cross-linking, influencing fibrosis, invasion, metastasis, angiogenesis, and mechanotransduction-related phenotypes. | Recent reviews and translational studies connect LOXL2 to fibrotic niche remodeling, myofibroblast biology, and tumor desmoplasia; Open Targets lists human disease associations including idiopathic pulmonary fibrosis. (pqac-00000001, pqac-00000000) | Moderate-high; disease linkage is strong, but many pathway assignments integrate direct and indirect effects of altered matrix mechanics. |
| 2023-2024 simtuzumab re-evaluation | Recent work argues failure of simtuzumab/AB0023 may reflect incomplete or nonproductive target modulation rather than invalidation of LOXL2 biology. | Espindola 2023 found anti-LOXL2 enhanced fibroblast-to-myofibroblast differentiation/invasion in translational IPF models and worsened fibrosis in humanized mice; normal/IPF fibroblast studies used n=4 per group and mouse studies n=3-5. Bell 2024 reported AB0023 did not significantly inhibit LOXL2 catalytic activity, collagen cross-linking, or tissue stiffness in disease-relevant fibrosis models. (pqac-00000006, pqac-00000008, pqac-00000009, pqac-00000010) | High that simtuzumab was ineffective; moderate that mechanism of failure is fully resolved. Negative antibody-trial results should not be overinterpreted as disproving LOXL2 as a target. |
| Clinical-stage inhibitors and trial status | Multiple LOXL2-directed or pan-LOX programs reached the clinic, but no LOX/LOXL2 inhibitor is yet approved. Simtuzumab failed in several phase 2 settings; newer small-molecule approaches remain under evaluation. | Simtuzumab IPF phase 2 RAINIER enrolled 544 and was terminated for lack of efficacy; PSC phase 2b enrolled 235; metastatic pancreatic cancer phase 2 enrolled 250; metastatic colorectal cancer phase 2 enrolled 266 and was terminated. Oral LOXL2 inhibitor GB2064 (formerly PAT-1251) phase IIa in myelofibrosis is active-not-recruiting, estimated n=21. Pan-LOX inhibitor PXS-5505 phase 1/2a in myelofibrosis completed with actual enrollment 43. (pqac-00000013, pqac-00000014, pqac-00000015, pqac-00000016, pqac-00000011, pqac-00000012) | High for trial status/enrollment. Caveat: some active programs are pan-LOX rather than LOXL2-selective, so clinical outcomes may not isolate LOXL2 biology alone. |


*Table: This table compacts the strongest available evidence for human LOXL2 functional annotation, from molecular mechanism and substrates to recent therapeutic re-evaluations. It is useful as a quick reference for separating well-established extracellular amine-oxidase functions from more tentative disease-mechanistic and translational claims.*